## Initial Evaluation of Persons With Chronic HCV



Kenneth E. Sherman, MD, PhD
Gould Professor of Medicine
Director, Division of Digestive Diseases
University of Cincinnati College of Medicine
Cincinnati, Ohio



### Disclosure Information (past 12 months)



- Research grants or contracts (awarded to his institution) from: Anadys, AbbVie, Bristol-Myers Squibb, Genentech, Gilead Sciences, Inc, Merck & Co, Inc, Vertex Pharmaceuticals, Inc
- Advisory board member or consultant to: Bioline, Kadmon, Merck & Co, Inc, MedPace, Janssen Therapeutics (formerly Tibotec), Roche Molecular

#### **Outline**



- Key aspects of history and physical examination
- Recommended laboratory studies after initial diagnosis
- Immunizations for persons with chronic hepatitis C virus (HCV)
- Screening for other causes and contributors of liver disease

# Key Aspects of History and Physical Examination





#### Key Aspects of History and Physical Examination

- Key elements of the patient's history
  - When and how diagnosed
  - Risk factors
    - Injection drug use: when, how long, rehab
    - Nasal cocaine
    - Blood transfusion
    - Tattoos and body piercing
    - Sexual exposures
    - Family exposures
  - Work-up to date
  - Prior treatment status
  - Comorbidities
    - Other known liver diseases, hepatotoxic drugs and alcohol
    - Cardiac, pulmonary, rheumatologic, neurologic
    - Psychiatric
  - Family history of liver disease
  - Current medications

### Key Aspects of History and Physical Examination (Continued)

- Physical exam
  - Eyes
    - Scleral icterus
    - Retinopathy on fundoscopic exam
  - Thyroid
    - Enlarged or nodular
  - Skin
    - × Jaundiced
    - × Palmar erythema
    - Spider angiomata
  - Lungs
    - × Right hydrothorax

- Cardiovascular
  - Rate and rhythm
- Abdomen
  - ★ Liver size and texture
  - x Spleen size
  - × Other masses
  - **Caput**
  - **Ascites**
- Neurologic
  - **Tremor**
  - **Asterixis**
- Psychiatric
  - x Mood and affect

### Recommended Laboratory Studies After Initial Diagnosis



### Recommended Laboratory Studies After Initial Diagnosis



#### General

- Hepatic profile
- Renal profile
- Complete blood cell count with differential
- Thyroid-stimulating hormone

#### Disease-related

- HCV RNA quantitative
- HCV genotype
- IL28B genotype
- Hepatitis B surface antibody (HBsAb)
- Anti-hepatitis A virus antibody immunoglobulin G (IgG)
- Alpha fetoprotein or baseline ultrasound

### Recommended Laboratory Studies After Initial Diagnosis (Continued)



- Determining whether advanced fibrosis or cirrhosis is present
  - Liver biopsy
  - Noninvasive markers
    - Proprietary indices (eg, FibroSure)
    - Nonproprietary indices (eg, AST-to-platelet ratio index, FIB-4 index)
  - Elastography
    - **Acoustic**
    - Magnetic resonance imaging

### Recommended Laboratory Studies After Initial Diagnosis (Continued)



- When advanced fibrosis or cirrhosis is present or suspected
  - Esophagogastroduodenoscopy (varices)
  - Ultrasound (hepatocellular carcinoma [HCC])
  - Model for End-Stage Liver Disease (MELD) evaluation
- Refer to transplant center
  - OMELD > 10
  - Any history of bleeding varices
  - Ascites
  - Hepatic encephalopathy

## Immunizations for Persons With Chronic HCV



#### **Immunizations for Persons With Chronic HCV**



#### Hepatitis A virus

- Test for hepatitis A antibody IgG
- Vaccinate twice, 6 months apart, or use combination vaccine

### Hepatitis B virus

- Test for HBsAb
- Vaccinate 3 times (0, 1, and 6 months) or use combination vaccine
- For immunosuppressed patients consider double-dose vaccine series

## Screening for Other Causes and Contributors of Liver Disease



### Screening for Other Causes and Contributors of Liver Disease



- Evaluation of other diseases optional but recommended if advanced fibrosis or cirrhosis is present
  - Alpha-1 antitrypsin deficiency
    - x Alpha-1 antitrypsin level
    - x Alpha-1 antitrypsin phenotype
  - Wilson disease
    - × Ceruloplasmin
    - ▼ Urinary copper

### Screening for Other Causes and Contributors of Liver Disease



- Autoimmune liver disease
  - × Antinuclear antibody
  - Antismooth muscle antibody
  - Antimichondrial antibody
  - Liver-kidney microsomal antibody type 1
- Genetic hemochromatosis
  - × Ferritin
  - x Iron saturation
- Nonalcoholic fatty liver and nonalcoholic steatohepatitis
  - x Homeostasis model assessment (fasting insulin and glucose)

### **Summary**



- Key elements for evaluation of a patient with HCV:
  - Detailed liver-focused history
  - Liver-directed physical examination
  - Evaluation of laboratory tests that help stage liver disease and determine if comorbidities are present
- Prevention of other liver diseases is important
  - Vaccinate for hepatitis A and B if necessary
- Determine if advanced fibrosis or cirrhosis is present
  - Refer to a hepatologist at a transplant center
  - Surveillance for varices and HCC is critical

#### **End**



This presentation is brought to you by the International Antiviral Society-USA (IAS-USA) in collaboration with Hepatitis Web Study & the Hepatitis C Online Course

Funded by a grant from the Centers for Disease Control and Prevention

